Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Eksakta : Berkala Ilmiah Bidang MIPA
Rosa, Feby Lilia
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Astronomy Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Civil Engineering, Building, Construction & Architecture Computer Science & IT Energy Engineering Environmental Science Materials Science & Nanotechnology Mathematics Mechanical Engineering

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Virtual Screening and Molecular Modelling Anticancer Molecules Targeting Fibroblast Growth Factor Receptor 4 Rosa, Feby Lilia; Fadilah, Fadilah; Erlina, Linda
EKSAKTA: Berkala Ilmiah Bidang MIPA Vol. 25 No. 03 (2024): Eksakta : Berkala Ilmiah Bidang MIPA (E-ISSN : 2549-7464)
Publisher : Faculty of Mathematics and Natural Sciences (FMIPA), Universitas Negeri Padang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24036/eksakta/vol25-iss03/464

Abstract

Cancer, characterized by uncontrolled cell proliferation, is a leading global cause of mortality. Targeting the fibroblast growth factor receptor (FGFR), a receptor tyrosine kinase (RTK), holds promise for anticancer drug development. FGFR4, a specific subtype, regulates various cellular processes, making it a valuable target. In-silico methods were employed to screen 20 compounds against FGFR4 (PDB ID 5JKG) using AutoDock Version 4.2.6. The top three potential inhibitors, based on Gibbs energy (ΔG) and inhibition constant (Ki), were identified: epigallocatechin3-O-pcoumarate (ΔG = -10.46 kcal/mol; Ki = 21.37 nM), 6_deoxoteasterone (ΔG = -10.22 kcal/mol; Ki = 32.35 nM), and epigallocatechin3-O-caffeate (ΔG = -9.78 kcal/mol; Ki = 68.16 nM). ADMETOX analysis confirmed compliance with Lipinski's rules, indicating their safety. These compounds show promise as FGFR4 inhibitors, potentially as standalone therapy or in combination with other anticancer drugs.
Co-Authors Erlina, Linda Fadilah Fadilah, Fadilah